Authors

Latest:

Dr. Ku on the Efficacy of Zanidatamab Plus Chemotherapy in HER2+ Gastroesophageal Adenocarcinoma

Geoffrey Y. Ku, MD, medical oncologist, discusses the efficacy of zanidatamab plus standard chemotherapy in patients with HER2-positive gastroesophageal adenocarcinoma in the ongoing phase 2 ZW25-201 trial.

George Ansstas, MD

Latest:

Evolving Treatment Options for Older Patients with AML

About 13,300 new cases of acute myeloid leukemia (AML) are diagnosed yearly, and nearly 9,000 deaths occur in the United States.

George D. Demetri, MD

Latest:

Dr. Demetri on Larotrectinib in TRK-Fusion GI Cancers

George D. Demetri, MD, director, Center for Sarcoma and Bone Oncology, senior vice president, Experimental Therapeutics, Dana-Farber Cancer Institute, professor of Medicine, Harvard Medical School, discusses the use of larotrectinib in patients with TRK-fusion gastrointestinal (GI) cancers.

George D. Demetri, MD, Dana-Farber Cancer Center

George Demetri, MD

Latest:

Dr. Demetri Discusses Regorafenib for GIST Patients

Dr. George Demetri, from Dana-Farber Cancer Institute, Discusses Regorafenib for Patients with GIST Trial Results.

George Kim, MD, 21st Century Oncology

George Kim, MD, University of Florida Health Oncology

George N. Ioannou, MD

Latest:

Dr. Ioannou on Treatment Options in Hepatocellular Carcinoma

George N. Ioannou, MD, associate professor, VA Puget Sound Health Care System, University of Washington School of Medicine, discusses the best treatment options for patients with hepatocellular carcinoma.

George P. Kim, MD

Latest:

Dr. Kim on PRODIGE 37 in Pancreatic Cancer

George P. Kim, MD, Orange Park Medical Center, discusses the results of the PRODIGE 37 trial in patients with pancreatic cancer.

George P. Kim, MD, 21st Century Oncology

George R. Blumenschein, MD

Latest:

Dr. Blumenschein on Immunotherapy Combinations in NSCLC

George R. Blumenschein, MD, department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses combinations with immunotherapy for patients with non-small cell lung cancer (NSCLC).

George R. Simon, MD

Latest:

Dr Simon on the ALK Inhibitor Selection Process in ALK+ NSCLC

George R Simon, MD, FACP, FCCP on selecting ALK inhibitors in ALK-positive non–small cell lung cancer.

George R. Simon, MD, FACP, FCCP

Latest:

Dr. Simon on the Impact of Immunotherapy Agents in NSCLC

George R. Simon, MD, FACP, FCCP, professor of medicine, The University of Texas MD Anderson Cancer Center, discusses how the introduction of immunotherapy in the treatment of patients with locally advanced, stage III non–small cell lung cancer (NSCLC) has affected prognosis.

George Sledge, Jr., MD

Latest:

Dr. Sledge on Genomic Sequencing in Patients With Breast Cancer

George Sledge, Jr., MD, discusses the benefit to the cost of genomic sequencing decreasing overtime.

George Somlo, MD

Latest:

Dr. George Somlo on Treatment Considerations for Multiple Myeloma

George Somlo, MD, medical oncologist, City of Hope, discusses treatment considerations in multiple myeloma.

George W. Sledge Jr, MD

Latest:

Looking for a Therapeutic Edge Among CDK Inhibitors

Whenever 3 agents joining the therapeutic armamentarium do so for similar indications with essentially identical mechanisms of action, it is reasonable to ask whether these agents have specific differences that might help decide which to use.

Georgia L. Wiesner, MD, MS

Latest:

Dr. Wiesner on Benefits of Genetic Testing in Colorectal Cancer

Georgia L. Wiesner, MD, MS, director, Clinical and Translational Hereditary Cancer Program, Ingram Professor of Cancer Research, professor of Medicine, cancer geneticist, Vanderbilt-Ingram Cancer Center, explains the benefits of genetic testing for colorectal cancer (CRC) and how oncologists can discuss it with their patients.

Georgina Long, BSc, MBBS, FRACP, Melanoma Institute of Australia

Georgina Long, BSc, PhD, MBBS, FRACP

Latest:

Dr Long on Unmet Needs in BRAF-Mutant Melanoma

Georgina Long, MBBS, PhD, FRACP, discusses unmet needs for BRAF-mutant melanoma, highlighting key insights from the phase 3 NADINA trial.

Georgina Long, MD, Melanoma Institute of Australia